Your guide to therapy with Beovu[®] (brolucizumab)

For the treatment of neovascular (wet) Age-related Macular Degeneration (AMD)



© 2025 Novartis UK | March 2025 | FA-11328017 MHRA approval date: 30 January 2025

What is neovascular (wet) age-related macular degeneration (AMD)?

Wet AMD occurs when abnormal blood vessels form and grow underneath the macula. The macula, which is at the back of the eye, is responsible for central vision. The abnormal blood vessels may leak fluid or blood into the eye and interfere with the macula's function, resulting in decreased vision.

Why have I been prescribed Beovu®?

Beovu[®] contains the active substance brolucizumab, which belongs to a group of medicines called anti-neovascularisation agents. Beovu[®] is injected into the eye (this is called an "intravitreal injection") to treat wet AMD in adults. Beovu[®] is usually given as a series of injections over a period of months or years.

A substance called vascular endothelial growth factor A (VEGF-A) causes the growth of blood vessels in the eye. By attaching to VEGF-A, Beovu[®] blocks its effect and reduces the growth of abnormal blood vessels in wet AMD, which in turn reduces the leakage of fluid or blood in the eye.

After treatment

- Your eyes will be assessed after your injection. In some cases this may include tests to measure the pressure inside your eye
- After the injection, you may experience a bloodshot eye, or see spots or a circle (air bubble) in your vision. These effects should improve within days. If they don't, or if they get worse, you should contact your doctor
- Sometimes, after an intravitreal injection such as Beovu[®], the following may occur:
 - An uncommon but severe inflammation usually associated with infection in the eye called "endophthalmitis"
 - Inflammation and/or blockage of the blood vessels at the back of the eye (retinal vasculitis or retinal vascular occlusion)
 - A temporary increase in eye pressure.
 This increase is common, but usually has no symptoms
- There is a possibility of retinal detachment (uncommon) or retinal tear (common)
- It is important to contact your doctor immediately if you experience any of these symptoms:
 - A sudden decrease or change in your vision, including an increased number of small particles or flashes of light
 - Pain, increased discomfort, or worsening redness in your eye
 - Increased sensitivity to light

What can I do after my treatment?

- After your injection, your vision may be temporarily affected (for example, blurred vision). Do not drive or use machines for as long as these side effects last
- Be proactive and tell your doctor or nurse if you notice any changes to your vision
- It is important to follow the visit schedule recommended by your doctor

Reporting side effects:

If you get side effects with any medication you are taking, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the information leaflet that comes in the pack. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. Please see www.mhra.gov.uk/yellowcard for instructions on how to report side effects.

How to contact your eye care clinic:

Contact:	
Telephone:	CLINIC CONTACT INFORMATION STAMP
Address:	
E-mail:	